🏅 Call for Applications for the 2025 Emerging Public Policy Leadership Award. 🏅

Founded in 1947, in 2022 AIBS celebrates its 75th anniversary

"What news from the sea?"

The fish replied: "I have a lot to say, but my mouth is full of water." - Armenian proverb

The San Diego, California shoreline. Credit: Frank McKenna

A small semi-transparent triangle for visual interest
Science Marches On

News & Events

Explore the most recent news about AIBS's initiatives, programs, resources, and events.

Bullet policy · Dec 07, 2020

CDC Recommends Who Should Get COVID-19 Vaccines First

On December 1, 2020, the Advisory Committee on Immunization Practices (ACIP)—a panel of independent scientific experts on vaccines that advises the Centers for Disease Control and Prevention (CDC)—approved the recommendation that health care personnel and residents of long-term care facilities should receive the first round of COVID-19 vaccinations.

Bullet awards, policy · Nov 11, 2020

Call for Applications: 2021 Emerging Public Policy and Leadership Award

Are you a science graduate student looking to make a difference in science policy and funding? The American Institute of Biological Sciences (AIBS) is now accepting applications for the 2021 Emerging Public Policy Leadership Award. This award recognizes graduate students in the biological sciences who are demonstrating an interest and aptitude for working at the intersection of science and policy.

Bullet policy · Nov 09, 2020

Science in the U.S. Elections

Former Vice President Joe Biden (D) has won the 2020 U.S. Presidential elections after securing narrow but crucial victories in the battleground states of Arizona and Pennsylvania. He is also currently leading in the vote tallies in Georgia.

Bullet policy · Oct 12, 2020

Trump Administration Proposes New Student Visa Restrictions

The Department of Homeland Security (DHS) issued a proposed rulemaking on September 25, 2020 that would impose new restrictions on international student visas. The proposed changes would require international students to apply for a visa extension after fixed terms of two to four years.

An icon of a paper airplane

Get the AIBS Newsletter

Our newsletter provides you with the very latest announcements & research from the world of biology, and updates automatically to reflect your personal interests. We also include news and events from AIBS & our 103 member societies. [Read about our data privacy.]

See an up-to-date example & subscribe 🗞 today!

Bullet policy · Oct 12, 2020

Science Associations Urge Rigorous Assessment of Vaccine Safety, Efficacy

AIBS has joined fourteen other scientific societies in urging Health and Human Services Secretary Alex Azar and Food and Drug Administration (FDA) Commissioner Stephen Hahn to adhere to stringent scientific and medical standards while assessing the safety and efficacy of COVID-19 vaccine candidates.

Bullet policy, statements · Oct 07, 2020

Joint Letter to OMB on Federal Diversity Training Changes

The undersigned scientific societies strongly urge the Administration to rescind its elimination of federal employee training programs related to diversity, equity and inclusion as specified in the Memorandum for the Heads of Executive Departments and Agencies issued September 4th, 2020 and the September 22nd Executive Order on Combating Race and Sex Stereotyping.
Bullet policy · Sep 28, 2020

WHO, NASEM Unveil COVID-19 Vaccine Allocation Plans

The World Health Organization (WHO) has released a preliminary framework for the global allocation of COVID-19 vaccines when they become available. The plan is intended to guide policymakers at the global, regional, and national level in their allocation and prioritization decisions about vaccines.

Bullet policy, statements · Sep 28, 2020

Multisociety Letter Urging Rigorous Assessment of COVID-19 Vaccine Safety and Efficacy

As representatives of hundreds of thousands of scientists across the country, we write to urge you to adhere to stringent scientific and medical standards as the Food and Drug Administration (FDA) prepares to assess the safety and efficacy of vaccine candidates that are currently in phase III clinical trials.